Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
You are here: Home / Latest news / News 2016 / GBMA welcomes Health Minister’s plans to streamline medicines regulation

GBMA welcomes Health Minister’s plans to streamline medicines regulation

September 16, 2016 By Emilia

15 September 2016

Australia can streamline the regulation of therapeutic goods by removing duplicative and inefficient processes without undermining the safety and quality of medicines, according to an independent review of medicines regulation.

The 2015 report of the Expert Review of Medicines and Medical Device Regulation makes 32 recommendations, many of which would improve regulatory efficiency and deliver more timely patient access to generic and biosimilar medicines.

An announcement today by Health Minister Sussan Ley to implement a number of these recommendations is welcomed by the Generic and Biosimilar Medicines Association (GBMA).

“Initiatives to drive regulatory efficiency and reduce the red-tape burden for generic and biosimilar medicine suppliers, without compromising on quality or safety, benefit patients, taxpayers and industry,” GBMA CEO, Belinda Wood said.

“GBMA is highly supportive of improvements in the regulation of medicines that will result in faster approval times for new generic and biosimilar medicines, streamlined administrative requirements and reduced costs for industry,”

“It currently takes just over a year for the Therapeutic Goods Administration (TGA) to evaluate and approve a generic medicine.  Reducing this time will bring new affordable medicines to patients sooner, increase treatment options for doctors and deliver savings for the PBS,”

“GBMA also welcomes the recommendation to streamline post-market requirements for medicines as it brings TGA processes in step with respected international regulatory bodies,”

“Enabling changes to products already in the Australian Register of Therapeutic Goods to be made faster, and with less red-tape, will ensure ongoing quality, patient safety and continuity of supply of affordable medicines.” she said.

-ENDS-

Filed Under: News 2016

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Mylan
Mylan
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
iqvia
iqvia
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

GBMA welcomes Fresenius Kabi Australia

October 4, 2019

4 October 2019 Canberra, ACT Canberra: Australia’s peak body representing generic and biosimilar manufacturers, the Generic and … More...

Federal Health Minister, Greg Hunt MP encourages healthcare sector to embrace biosimilar medicines.

October 2, 2019

2 October 2019 Doctors, pharmacists, medical researchers, and hospital leaders attend 'Your … More...

GBMA welcomes new appointment to the Board

September 30, 2019

30 September 2019 Canberra, ACT The nation’s peak body for generic and biosimilar … More…

© 2019 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us